National Academies Press: OpenBook
« Previous: Origins of the Immunization Safety Review Project
Suggested Citation:"The Charge of the Committee." Institute of Medicine. 2001. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. Washington, DC: The National Academies Press. doi: 10.17226/10208.
×
Page 22

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

22 IMMUNIZATION SAFETY RE VIE W year of discussions with IOM to develop the Immunization Safety Review proj- ect to address vaccine safety issues both existing and emerging. THE CHARGE TO THE COMMITTEE The Immunization Safety Review Committee is responsible for examining a broad variety of vaccine safety concerns. Committee members have expertise in pediatrics, neurology, immunology, internal medicine, infectious diseases, ge- netics, epidemiology, biostatistics, risk perception and communication, decision analysis, public health, nursing, and ethics. While all the committee members share the view that vaccination is beneficial, none of them has a vested interest in the vaccine safety issues that will come before the group. Additional discus- sion of the committee composition can be found in the Foreword, written by Dr. Kenneth Shine, President of the IOM. The committee is charged with examining three vaccine safety hypotheses each year during the three-year study period (2001-2003~. The Interagency Vaccine Group made up of officials from the National Vaccine Program Of- fice at DHHS, the National Immunization Program and the National Center for Infectious Diseases at the CDC, the National Institute for Allergy and Infectious Diseases at the NIH, the Department of Defense, the FDA, the National Vaccine Injury Compensation Program at HRSA, the Health Care Financing Administra- tion, and the Agency for International Development selects the hypotheses to be examined by the committee. For each of these, the committee reviews rele- vant literature and submissions by interested parties, and it holds an open scien- tific meeting followed directly by a one- to two-day closed meeting to formulate its conclusions and recommendations. The committee's findings are released to the public in a brief consensus report 60-90 days after its meeting. For each hypothesis to be examined, the committee has been asked to assess both the scientific plausibility of the issue and its significance in a broader so- cietal context. The plausibility assessment has two components: an examination of any pathogenic mechanisms relevant to the hypothesis (also known as bio- logic plausibility), and an examination of the evidence regarding a possible causal relationship between the vaccine and the adverse event. The significance assessment addresses such considerations as the nature of the health risks asso- ciated with the vaccine-preventable disease and with the adverse event in ques- tion. Other considerations may include the perceived intensity of public or pro- fessional concern, or the feasibility of additional research to help resolve scientific uncertainty regarding causal associations. The findings of the plausibility and significance assessments provide the basis for the committee's recommendations on public health response, which includes immunization policy review, current and future research, and effective communi- cation strategies for the specific immunization safety questions. Although the committee has been asked to make recommendations related to immunization

Next: The Study Process The Framework for Assessing Causality »
Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders Get This Book
×
Buy Paperback | $45.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

In this report, the Immunization Safety Review committee examines the hypothesis of whether or not the use of vaccines containing the preservative thimerosal can cause neurodevelopmental disorders (NDDs), specifically autism, attention deficit/hyperactivity disorder (ADHD), and speech or language delay.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!